Research News

From Personal Loss to Professional Passion: A Researcher’s Dedication to Transforming Patients’ Lives When Tycel Phillips, MD, of City of Hope, was a young child growing up in Chicago, his grandmother gave him an anatomy book as a gift. And…

The Lymphoma Research Foundation’s Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma and CLL research, whether in the lab or in the clinic.

Thomas Habermann, MD, a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, and former Chair of the Lymphoma Research Foundation’s Scientific Advisory Board (SAB) brings passion and drive to every study he works on and every patient he works with.

The 16 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.

Updates from the 2023 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 318 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…

ASH 2023: Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in the Tumor Microenvironment Cancer cells routinely reprogram cellular metabolism to improve their fitness, providing a selective advantage that supports growth and expansion. Researchers previously determined…

ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies The treatment landscape of large B-cell lymphomas (LBCL) has changed dramatically in recent years, driven in part…

ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment options for relapsed or refractory peripheral T-cell lymphoma (PTCL) are limited, and many patients experience an aggressive disease course. In the phase 2 VALENTINE-PTCL01 study,…

ASH 2023: Overall Survival in Mantle Cell Lymphoma Has Improved in the Era of Targeted Therapies Mantle cell lymphoma (MCL) has historically been treated using combination chemoimmunotherapy followed by stem cell transplant and has been associated with poor survival outcomes.…